121 related articles for article (PubMed ID: 21418740)
1. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells.
Can G; Ekiz HA; Baran Y
Hematology; 2011 Mar; 16(2):95-9. PubMed ID: 21418740
[TBL] [Abstract][Full Text] [Related]
2. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.
Yu Y; Yang L; Zhao M; Zhu S; Kang R; Vernon P; Tang D; Cao L
Leukemia; 2012 Aug; 26(8):1752-60. PubMed ID: 22395361
[TBL] [Abstract][Full Text] [Related]
3. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
4. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
Shao S; Li S; Qin Y; Wang X; Yang Y; Bai H; Zhou L; Zhao C; Wang C
Int J Oncol; 2014 May; 44(5):1661-8. PubMed ID: 24585095
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.
Drullion C; Trégoat C; Lagarde V; Tan S; Gioia R; Priault M; Djavaheri-Mergny M; Brisson A; Auberger P; Mahon FX; Pasquet JM
Cell Death Dis; 2012 Aug; 3(8):e373. PubMed ID: 22898871
[TBL] [Abstract][Full Text] [Related]
6. [Autophagy in hematologic malignancies].
Adachi S
Rinsho Ketsueki; 2009 Oct; 50(10):1531-8. PubMed ID: 19915363
[No Abstract] [Full Text] [Related]
7. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
8. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
9. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
10. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
[TBL] [Abstract][Full Text] [Related]
11. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.
Gucluler G; Baran Y
Hematology; 2009 Jun; 14(3):139-44. PubMed ID: 19490758
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
14. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
Crowley LC; Elzinga BM; O'Sullivan GC; McKenna SL
Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
[TBL] [Abstract][Full Text] [Related]
15. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
[TBL] [Abstract][Full Text] [Related]
17. Appropriate modulation of autophagy sensitizes malignant peripheral nerve sheath tumor cells to treatment with imatinib mesylate.
Okano M; Sakata N; Ueda S; Takemura T
J Pediatr Hematol Oncol; 2014 Apr; 36(3):200-11. PubMed ID: 24136016
[TBL] [Abstract][Full Text] [Related]
18. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
